Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer initiates phase III trial of lung cancer drug

Pfizer initiates phase III trial of lung cancer drug

29th June 2011

Pfizer has announced the commencement of a new phase III trial of an investigational lung cancer treatment, PF-299.

The study, which has now begun enrolment in the US before rolling out internationally, is set to compare the oral pan-HER inhibitor to erlotinib among non-small cell lung cancer (NSCLC) patients whose conditions have proven resistant to chemotherapy.

It will particularly examine the performance of PF-299 among KRAS wild-type status patients, with safety and efficacy being the primary endpoint targets of the trial.

Pfizer has initiated this new study based on positive results from an earlier phase II trial, data from which will be presented for the first time at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

Dr Maurizio Voi, thoracic tumour strategy lead at Pfizer Oncology, said: "Data being presented shows survival outcomes for PF-299 … as well as quality-of-life or patient-reported outcomes after treatment for patients with NSCLC, which represent important considerations in determining the best treatment option."

Last week, the company published new clinical trial data demonstrating the efficacy of Lyrica as a treatment for central neuropathic pain following spinal cord injury.ADNFCR-8000103-ID-800603045-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.